Fluor bags award for Biologics manufacturing facility in Scandinavia
Construction is now underway with the facility scheduled to be operational by 2025
Construction is now underway with the facility scheduled to be operational by 2025
The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
The companies have also initiated a Phase 1/2/3 study NCT05543616 to evaluate the safety, tolerability, and immunogenicity of different doses
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Dolomite Bio scientist demonstrating pipetting into the Nadia Go
Cytel has now established entities in Australia, Shanghai, Beijing, and Singapore, and plans to expand into Seoul and Tokyo in the coming years.
They also noted ProBioGen's digitalization investments and strategy, as well as its support for its employees.
The reliability of their products, evidenced by their inclusion in the WHO emergency use list, has further improved with the addition of Takara Bio's enzymes.
Subscribe To Our Newsletter & Stay Updated